New Animal Drugs; Withdrawal of Approval of a New Animal Drug Application, 32188-32189 [2017-14566]
Download as PDF
32188
Federal Register / Vol. 82, No. 132 / Wednesday, July 12, 2017 / Notices
increasing the probability that
customers would pay higher prices for
fibre channel switches and that
innovation would be lessened.
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Entry
Entry into the worldwide fibre
channel switch market is not likely to
occur in a timely, likely, or sufficient
magnitude, character and scope to deter
or counteract any anticompetitive
effects created by the proposed
Acquisition. Entry is unlikely in light of
slowly declining demand for fibre
channel switches in a mature market,
customers that tend to stay with one
fibre channel switch manufacturer for
extended periods of time, and the
significant capital costs required for
entry.
The Consent Agreement
To remedy the alleged competitive
concern stemming from Broadcom’s
access to Cisco’s competitively sensitive
confidential information, the consent
decree prevents the Cisco information
from being shared among Broadcom
employees who could use such
information to raise prices or lessen
innovation.
Pursuant to the proposed Order, only
authorized individuals will have access
to Cisco’s competitively sensitive
confidential information that is given to
the firewalled entity, which is defined
as Broadcom’s business group
responsible for the development,
production, sale, and marketing of fibre
channel ASICs for Cisco. The firewalled
entity will have separate facilities and a
separate information technology system
with security protocols assuring access
only to the authorized individuals.
Furthermore, Broadcom shall require all
authorized individuals to sign a nondisclosure agreement, requiring
compliance with the terms of the
proposed Order. Additionally, the
proposed Order provides for a cooling
off period whereby any authorized
individual who leaves his or her
position at the firewalled entity will not
work in the development, production,
sale, or marketing of fibre channel
ASICs for Brocade’s business unit or in
the development, production, sales, and
marketing of fibre channel switches for
twelve months.
The proposed Order also requires
Broadcom to use Cisco’s competitively
sensitive confidential information only
in furtherance of the design,
manufacturing, and sale of fibre channel
ASICs for Cisco. Moreover, Broadcom
will be required to take all actions
necessary to prevent access to, or the
disclosure or use of Cisco’s
competitively sensitive confidential
VerDate Sep<11>2014
17:54 Jul 11, 2017
Jkt 241001
information by or to anyone who is not
an authorized individual. The proposed
Order also incorporates by reference
non-disclosure provisions contained in
four prior private Confidentiality
Agreements that Broadcom, or its
predecessor, signed with Cisco.
To ensure compliance with the
proposed Order, the Commission will
appoint a Monitor to oversee
Broadcom’s and Brocade’s performance
of their obligations pursuant to the
Consent Agreement. The Monitor will
be appointed to a five-year term, but the
Commission may extend or modify the
term as appropriate up to a ten-year
period. Further, the Consent Agreement
contains appropriate reporting
requirements.
Opportunity for Public Comment
The purpose of this analysis is to
facilitate public comment on the
proposed Consent Agreement to aid the
Commission in determining whether it
should make the proposed Consent
Agreement final. This analysis is not an
official interpretation of the proposed
Consent Agreement and does not
modify its terms in any way.
By direction of the Commission.
Donald S. Clark,
Secretary.
[FR Doc. 2017–14536 Filed 7–11–17; 8:45 am]
BILLING CODE 6750–01–P
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Claudette Grant,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. 2017–14745 Filed 7–10–17; 4:15 pm]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2017–N–0002]
New Animal Drugs; Withdrawal of
Approval of a New Animal Drug
Application
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of withdrawal.
The Food and Drug
Administration (FDA) is withdrawing
approval of two new animal drug
applications (NADAs). This action is
being taken at the sponsor’s request
because these products are no longer
manufactured or marketed.
SUMMARY:
Withdrawal of approval is
effective July 24, 2017.
DATES:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Sunshine Act Meeting: Board of
Scientific Counselors NCEH/ATSDR;
Cancelation
FEDERAL REGISTER CITATION OF PREVIOUS
ANNOUNCEMENT: The original Federal
Register Notice for this meeting was
published in the Federal Register on
May 22, 2017, Volume 82, Number
2017–10333, page/s/23250–23251.
PREVIOUSLY ANNOUNCED TIME AND DATE OF
THE MEETING: 9:00 a.m.–noon, EDT, June
23, 2017.
This meeting is
being canceled in its entirety.
CONTACT PERSON FOR MORE INFORMATION:
Amanda Malasky, BS, ORISE Fellow,
CDC, 4770 Buford Hwy., Atlanta, GA
30344, telephone 770–488–7699; yoo0@
cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
CHANGES IN THE MEETING:
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
FOR FURTHER INFORMATION CONTACT:
Sujaya Dessai, Center for Veterinary
Medicine (HFV–212), Food and Drug
Administration, 7519 Standish Pl.,
Rockville, MD 20855, 240–402–5761,
sujaya.dessai@fda.hhs.gov.
Zoetis,
Inc., 333 Portage St., Kalamazoo, MI
49007 has requested that FDA withdraw
approval of NADA 065–291 for bulk
dihydrostreptomycin sulfate and NADA
065–324 for bulk streptomycin sulfate
because the products are no longer
manufactured or marketed.
Therefore, under authority delegated
to the Commissioner of Food and Drugs,
and in accordance with § 514.116 Notice
of withdrawal of approval of application
(21 CFR 514.116), notice is given that
approval of NADA 065–291 and NADA
065–324, and all supplements and
amendments thereto, is hereby
withdrawn, effective July 24, 2017.
As neither of these NADAs was
codified, the animal drug regulations do
not require amendment to reflect the
voluntary withdrawal of approval of
these applications.
SUPPLEMENTARY INFORMATION:
E:\FR\FM\12JYN1.SGM
12JYN1
Federal Register / Vol. 82, No. 132 / Wednesday, July 12, 2017 / Notices
Dated: July 7, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
[FR Doc. 2017–14566 Filed 7–11–17; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Cancer
Institute Special Emphasis Panel, July
20, 2017, 11:00 a.m. to July 20, 2017,
05:00 p.m., National Cancer Institute
Shady Grove, Shady Grove, 9609
Medical Center Drive, 7W102,
Rockville, MD 20850 which was
published in the Federal Register on
May 31, 2017, 82 FR 24983.
The meeting notice is amended to
change the meeting title to ‘‘Core
Infrastructure & Epidemiology Cohorts’’.
The meeting date has been changed to
August 8, 2017 and the contact person
has been changed to Shakeel Ahmad,
Ph.D.; phone 240–276–6349; ahmads@
mail.nih.gov. The meeting is closed to
the public.
Name of Committee: National Institute on
Aging Special Emphasis Panel; The Dog
Aging Project.
Date: August 4, 2017.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 2W200, 7201 Wisconsin
Ave., Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Isis S. Mikhail, DRPH, MD,
MPH, National Institute on Aging, Gateway
Building, 7201 Wisconsin Avenue, Suite
2C212, Bethesda, MD 20892, 301–402–7704,
MIKHAILI@MAIL.NIH.GOV.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: July 6, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
asabaliauskas on DSKBBXCHB2PROD with NOTICES
National Institutes of Health
VerDate Sep<11>2014
17:54 Jul 11, 2017
Jkt 241001
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Coast Guard
[Docket No. USCG–2016–1084]
Navigation and Vessel Inspection
Circular (NVIC) 05–17; Guidelines for
Addressing Cyber Risks at Maritime
Transportation Security Act (MTSA)
Regulated Facilities
ACTION:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
SUMMARY:
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meeting
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Myocardial
Ischemia and Metabolism Members Conflict.
Date: August 1–2, 2017.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Abdelouahab Aitouche,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4222,
MSC 7814, Bethesda, MD 20892, 301–435–
2365, aitouchea@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2017–14538 Filed 7–11–17; 8:45 am]
AGENCY:
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
BILLING CODE 4140–01–P
Dated: July 6, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
BILLING CODE 4140–01–P
National Institute on Aging; Notice of
Closed Meeting
[FR Doc. 2017–14539 Filed 7–11–17; 8:45 am]
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
[FR Doc. 2017–14540 Filed 7–11–17; 8:45 am]
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Dated: July 6, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
32189
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
Coast Guard, DHS.
Notice of availability and
request for comments.
The Coast Guard announces
the availability of draft Navigation and
Inspection Circular (NVIC) 05–17;
Guidelines for Addressing Cyber Risks
at Maritime Transportation Security Act
(MTSA) Regulated Facilities, and
requests public comment on the draft.
This NVIC proposes to clarify the
existing requirements under MTSA to
incorporate analysis of computer and
cyber risks and guidance for addressing
those risks. This NVIC would provide
guidance on incorporating cybersecurity
risks into an effective Facility Security
Assessment (FSA), as well as additional
recommendations for policies and
procedures that may reduce cyber risk
to operators of maritime facilities.
Operators may use this document as a
benchmark to develop and implement
measures and activities for effective selfgovernance of cyber risks.
DATES: Comments must be submitted to
the online docket via https://
www.regulations.gov, or reach the
Docket Management Facility, on or
before September 11, 2017.
FOR FURTHER INFORMATION CONTACT: If
you have questions on this notice, call
or email, Jason Warren, Coast Guard;
telephone 202–372–1106, email
Jason.S.Warren@uscg.mil or LCDR
Josephine Long, Coast Guard; telephone
202–372–1109, email
Josephine.A.Long@uscg.mil.
ADDRESSES: You may submit comments
identified by docket number USCG–
2016–1084 using the Federal
eRulemaking Portal at https://
www.regulations.gov. See the ‘‘Public
Participation and Request for
Comments’’ portion of the
E:\FR\FM\12JYN1.SGM
12JYN1
Agencies
[Federal Register Volume 82, Number 132 (Wednesday, July 12, 2017)]
[Notices]
[Pages 32188-32189]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-14566]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2017-N-0002]
New Animal Drugs; Withdrawal of Approval of a New Animal Drug
Application
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of withdrawal.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval
of two new animal drug applications (NADAs). This action is being taken
at the sponsor's request because these products are no longer
manufactured or marketed.
DATES: Withdrawal of approval is effective July 24, 2017.
FOR FURTHER INFORMATION CONTACT: Sujaya Dessai, Center for Veterinary
Medicine (HFV-212), Food and Drug Administration, 7519 Standish Pl.,
Rockville, MD 20855, 240-402-5761, sujaya.dessai@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Zoetis, Inc., 333 Portage St., Kalamazoo, MI
49007 has requested that FDA withdraw approval of NADA 065-291 for bulk
dihydrostreptomycin sulfate and NADA 065-324 for bulk streptomycin
sulfate because the products are no longer manufactured or marketed.
Therefore, under authority delegated to the Commissioner of Food
and Drugs, and in accordance with Sec. 514.116 Notice of withdrawal of
approval of application (21 CFR 514.116), notice is given that approval
of NADA 065-291 and NADA 065-324, and all supplements and amendments
thereto, is hereby withdrawn, effective July 24, 2017.
As neither of these NADAs was codified, the animal drug regulations
do not require amendment to reflect the voluntary withdrawal of
approval of these applications.
[[Page 32189]]
Dated: July 7, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.
[FR Doc. 2017-14566 Filed 7-11-17; 8:45 am]
BILLING CODE 4164-01-P